<DOC>
	<DOCNO>NCT02953509</DOCNO>
	<brief_summary>This Phase 1b/2 trial evaluate Hu5F9-G4 combination rituximab . Hu5F9-G4 monoclonal antibody design block protein call CD47 , widely express human cancer cell . Blocking CD47 Hu5F9-G4 may enable body 's immune system find destroy cancer cell . Rituximab monoclonal antibody drug use treatment non-Hodgkin 's lymphoma type cancer . The major aim trial : ( Phase 1b ) investigate safety tolerability sequential dose cohort determine recommend Phase 2 dose Hu5F9-G4 combination rituximab , ( Phase 2 ) evaluate efficacy Hu5F9-G4 combination rituximab patient indolent lymphoma diffuse large B-cell lymphoma measure overall response rate .</brief_summary>
	<brief_title>Trial Hu5F9-G4 Combination With Rituximab Relapsed/Refractory B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Phase 1b : Bcell nonHodgkin 's lymphoma ( NHL ) , relapse refractory standard approve therapy DLBCL Phase 2 cohort : De novo transform diffuse large Bcell lymphoma ( DLBCL ) , relapse refractory frontline second line treatment autologous hematopoietic cell transplantation Indolent lymphoma Phase 2 cohort : Marginal zone follicular lymphoma , relapse refractory standard approve therapy Adequate performance status hematological , liver kidney function Phase 2 : Willing consent 1 mandatory pretreatment 1 ontreatment tumor biopsy Active brain metastasis Prior allogeneic hematopoietic cell transplantation Prior treatment CD47 signal regulatory protein alpha ( SIRPÎ± ) target agent Second malignancy within last 3 year Known active chronic hepatitis B C infection HIV Pregnancy active breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>indolent lymphoma</keyword>
	<keyword>Hu5F9-G4</keyword>
	<keyword>CD47</keyword>
</DOC>